James Brett Case

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1115987/publications.pdf Version: 2024-02-01



IAMES RDETT CASE

#	Article	lF	CITATIONS
1	Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature, 2020, 583, 290-295.	27.8	1,695
2	Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature, 2020, 584, 443-449.	27.8	956
3	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nature Medicine, 2021, 27, 717-726.	30.7	838
4	SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature, 2021, 596, 109-113.	27.8	586
5	Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nature Immunology, 2020, 21, 1506-1516.	14.5	563
6	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science, 2020, 370, 950-957.	12.6	504
7	A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. Cell, 2020, 182, 744-753.e4.	28.9	486
8	SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature, 2022, 603, 687-692.	27.8	475
9	De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science, 2020, 370, 426-431.	12.6	464
10	Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nature Medicine, 2020, 26, 1422-1427.	30.7	450
11	A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. Cell, 2020, 183, 169-184.e13.	28.9	446
12	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. Cell Host and Microbe, 2020, 28, 475-485.e5.	11.0	380
13	The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell, 2021, 184, 2183-2200.e22.	28.9	331
14	Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell, 2021, 184, 1804-1820.e16.	28.9	297
15	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nature Microbiology, 2021, 6, 1233-1244.	13.3	237
16	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature, 2021, 596, 103-108.	27.8	222
17	Growth, detection, quantification, and inactivation of SARS-CoV-2. Virology, 2020, 548, 39-48.	2.4	209
18	Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 32105-32113.	7.1	192

JAMES BRETT CASE

#	Article	IF	CITATIONS
19	A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. Journal of Immunology, 2020, 205, 915-922.	0.8	186
20	Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. Cell Host and Microbe, 2020, 28, 465-474.e4.	11.0	156
21	Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 20803-20813.	7.1	154
22	A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Reports, 2021, 36, 109400.	6.4	119
23	Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays. Clinical Chemistry, 2020, 66, 1538-1547.	3.2	112
24	A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. Cell Reports Medicine, 2021, 2, 100230.	6.5	99
25	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell Reports, 2021, 37, 110143.	6.4	94
26	Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nature Communications, 2022, 13, .	12.8	93
27	A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. Immunity, 2021, 54, 2399-2416.e6.	14.3	79
28	LDLRAD3 is a receptor for Venezuelan equine encephalitis virus. Nature, 2020, 588, 308-314.	27.8	78
29	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. Science Translational Medicine, 2022, 14, .	12.4	73
30	Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. Cell, 2022, 185, 1572-1587.e11.	28.9	71
31	Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice. Science Translational Medicine, 2022, 14, eabn1252.	12.4	68
32	SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice. Journal of Virology, 2022, 96, JVI0151121.	3.4	58
33	A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. Immunity, 2021, 54, 2159-2166.e6.	14.3	52
34	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants. Cell Host and Microbe, 2022, 30, 53-68.e12.	11.0	52
35	On the road to ending the COVID-19 pandemic: Are we there yet?. Virology, 2021, 557, 70-85.	2.4	38
36	Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. Cell Host and Microbe, 2021, 29, 1151-1161.e5.	11.0	36

JAMES BRETT CASE

#	Article	IF	CITATIONS
37	Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations. Journal of Molecular Biology, 2021, 433, 167177.	4.2	31
38	The Translational Landscape of SARS-CoV-2-infected Cells Reveals Suppression of Innate Immune Genes. MBio, 2022, 13, .	4.1	21
39	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. SSRN Electronic Journal, 2020, , 3606354.	0.4	16
40	Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting. Cell Reports, 2022, 38, 110561.	6.4	16
41	Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD. Cell Reports, 2021, 37, 109881.	6.4	14
42	JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis. MBio, 2022, 13, e0337721.	4.1	14
43	An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer. Journal of Clinical Investigation, 2022, 132, .	8.2	14
44	Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors. MBio, 2022, 13, e0323821.	4.1	11
45	Ultrapotent and broad neutralization of SARS-CoV-2 variants by modular, tetravalent, bi-paratopic antibodies. Cell Reports, 2022, 39, 110905.	6.4	5